193 related articles for article (PubMed ID: 8111815)
1. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis.
Ettinger B
Clin Ther; 1993; 15(6):950-62; discussion 949. PubMed ID: 8111815
[TBL] [Abstract][Full Text] [Related]
2. Osteoporosis: new hope for the future.
Masi L; Bilezikian JP
Int J Fertil Womens Med; 1997; 42(4):245-54. PubMed ID: 9309458
[TBL] [Abstract][Full Text] [Related]
3. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
4. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy.
Prince RL; Smith M; Dick IM; Price RI; Webb PG; Henderson NK; Harris MM
N Engl J Med; 1991 Oct; 325(17):1189-95. PubMed ID: 1922205
[TBL] [Abstract][Full Text] [Related]
5. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy.
Sulak PJ; Caubel P; Lane R
Int J Fertil Womens Med; 1999; 44(6):286-96. PubMed ID: 10617250
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
[TBL] [Abstract][Full Text] [Related]
8. Unopposed estradiol therapy in postmenopausal women: results from two randomized trials.
Steiner AZ; Xiang M; Mack WJ; Shoupe D; Felix JC; Lobo RA; Hodis HN
Obstet Gynecol; 2007 Mar; 109(3):581-7. PubMed ID: 17329508
[TBL] [Abstract][Full Text] [Related]
9. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
Josse RG
CMAJ; 1996 Oct; 155(7):929-34. PubMed ID: 8837542
[TBL] [Abstract][Full Text] [Related]
10. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
[TBL] [Abstract][Full Text] [Related]
11. HRT dosing regimens: continuous versus cyclic-pros and cons.
Shoupe D
Int J Fertil Womens Med; 2001; 46(1):7-15. PubMed ID: 11294619
[TBL] [Abstract][Full Text] [Related]
12. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T;
BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy in postmenopausal women.
Yasui T; Uemura H; Takikawa M; Irahara M
J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
[TBL] [Abstract][Full Text] [Related]
14. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Christiansen C
Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
[TBL] [Abstract][Full Text] [Related]
15. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
Bunyavejchevin S; Limpaphayom KK
J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
[TBL] [Abstract][Full Text] [Related]
16. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone.
Ferenczy A; Gelfand MM; van de Weijer PH; Rioux JE
Climacteric; 2002 Mar; 5(1):26-35. PubMed ID: 11974556
[TBL] [Abstract][Full Text] [Related]
17. Postmenopausal osteoporosis and hormone replacement therapy.
Gambacciani M; Vacca F
Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
[TBL] [Abstract][Full Text] [Related]
18. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
19. Clinical effects of 17 beta-estradiol and norethisterone acetate in postmenopausal Thai women.
Limpaphayom KK; Bunyavejchevin S
J Med Assoc Thai; 2000 Apr; 83(4):407-16. PubMed ID: 10808701
[TBL] [Abstract][Full Text] [Related]
20. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
Reed SD; Newton KM; LaCroix AZ; Grothaus LC; Grieco VS; Ehrlich K
Menopause; 2008; 15(1):51-8. PubMed ID: 18257142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]